Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.325 USD | -0.42% | -5.63% | +159.44% |
May. 28 | Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion | MT |
May. 15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+159.44% | 968M | |
+15.13% | 118B | |
+13.08% | 106B | |
-2.83% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-16.87% | 15.56B | |
+4.84% | 13.63B | |
+28.67% | 12.27B |
- Stock Market
- Equities
- ARQT Stock
- News Arcutis Biotherapeutics, Inc.
- Arcutis Biotherapeutics Says Atopic Dermatitis Cream Met Primary Endpoint in Phase 3 Study in Children